As of 2025-07-08, the Intrinsic Value of Talis Biomedical Corp (TLIS) is 2.04 USD. This TLIS valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 4.38 USD, the upside of Talis Biomedical Corp is -53.30%.
The range of the Intrinsic Value is 2.51 - 1.67 USD
Based on its market price of 4.38 USD and our intrinsic valuation, Talis Biomedical Corp (TLIS) is overvalued by 53.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (50.90) - 1.70 | (1.73) | -139.6% |
| DCF (Growth 10y) | 1.29 - (52.15) | (2.21) | -150.4% |
| DCF (EBITDA 5y) | 2.51 - 1.67 | 2.04 | -53.3% |
| DCF (EBITDA 10y) | 2.11 - 0.98 | 1.52 | -65.2% |
| Fair Value | -24.66 - -24.66 | -24.66 | -663.06% |
| P/E | (146.20) - (168.10) | (144.89) | -3408.0% |
| EV/EBITDA | (58.40) - 6.30 | (30.03) | -785.6% |
| EPV | (127.28) - (175.47) | (151.38) | -3556.1% |
| DDM - Stable | (53.01) - (319.03) | (186.02) | -4347.0% |
| DDM - Multi | (1.92) - (9.34) | (3.23) | -173.6% |
| Market Cap (mil) | 45.31 |
| Beta | 1.17 |
| Outstanding shares (mil) | 10.35 |
| Enterprise Value (mil) | -14.56 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.74% |
| Cost of Debt | 5.00% |
| WACC | 5.71% |